Pharmaceutical patents in Europe:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
The Hague [u.a.]
Kluwer Law International [u.a.]
2000
|
| Schriftenreihe: | Stockholm studies in law
|
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes index |
| Beschreibung: | 364 S. |
| ISBN: | 9041113487 9139006018 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV021451552 | ||
| 003 | DE-604 | ||
| 005 | 20091216 | ||
| 007 | t | ||
| 008 | 000731s2000 |||| 00||| eng d | ||
| 020 | |a 9041113487 |9 90-411-1348-7 | ||
| 020 | |a 9139006018 |9 91-39-00601-8 | ||
| 035 | |a (OCoLC)247401924 | ||
| 035 | |a (DE-599)BVBBV021451552 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-M382 |a DE-188 | ||
| 082 | 0 | |a 346.40486 | |
| 100 | 1 | |a Domeij, Bengt |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical patents in Europe |c Bengt Domeij |
| 264 | 1 | |a The Hague [u.a.] |b Kluwer Law International [u.a.] |c 2000 | |
| 300 | |a 364 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Stockholm studies in law | |
| 500 | |a Includes index | ||
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014671818&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014671818 | ||
Datensatz im Suchindex
| _version_ | 1804135172740743168 |
|---|---|
| adam_text | BENGT DOMEIJ PHARMACEUTICAL PATENTS IN EUROPE INTERNATIONAL THE HAGUE *
LONDON * BOSTON NORSTEDTS JURIDIK STOCKHOLM CONTENTS ACKNOWLEDGEMENTS 7
FOREWORD 8 ABBREVIATIONS 17 1. INDUSTRIAL APPLICABILITY 19 1.1
INDUSTRIAL APPLICABILITY OF PHARMACEUTICAL PRODUCT PATENTS 19 1.2
REMARKS 25 1.3 INDUSTRIAL APPLICABILITY OF MEDICAL PROCESSES 30 1.3.1
PROCESSES APPLIED TO THE HUMAN OR ANIMAL BODY 30 1.3.2 THERAPY 31 1.3.3
DIAGNOSIS 35 1.3.4 REMARKS 38 2. SUFFICIENCY OF DISCLOSURE 45 2.1
DISCLOSURES OF INVENTIONS 45 2.2 THE MAN SKILLED IN THE ART 47 2.2.1 THE
DIFFERENT ASPECTS OF THE MAN SKILLED IN THE ART 47 2.2:2 THE SCOPE OF
KNOWLEDGE 48 2.2.3 THE AVERAGE KNOWLEDGE 52 2.2.4 THE EFFORT TO BE MADE
BY THE SKILLED PERSON 55 2.2.5 PARTS OF THE PATENT APPLICATION THAT THE
SKILLED MAN MAY USE 58 2.3 REMARKS 60 3. THE CLAIMS 63 3.1 TWO PURPOSES
63 3.2 CLARITY. . 64 3.2.1 GENERAL RULES 64 3.2.2 CLARITY AND BROAD
CLAIMS 65 3.2.3 DEFINITIONS OF CHEMICAL COMPOUNDS 67 3.2.3.1 STRUCTURAL
FORMULA 68 3.2.3.2 PRODUCT-BY-PROCESS CLAIMS 68 3.2.3.3 PARAMETERS IN
THE CLAIMS 69 14 CONTENTS 3.3 THE RELATIONSHIP BETWEEN THE INVENTION AND
THE SCOPE OF PROTECTION 73 3.3.1 INTRODUCTION 73 3.3.2 THE OUTLINE OF
THE STUDY 74 3.3.3 STRUCTURAL FEATURES - MARKUSH CLAIMS 76 3.3.3.1
PROCEDURAL RULES 80 3.3.3.2 NON-FUNCTIONAL PARTS OF THE CLAIMS 82
3.3.3.3 REMARKS 85 3.3.4 FUNCTIONAL FEATURES 104 3.3.4.1 FUNCTIONAL
FEATURES - PARTICULARLY IN BIOTECHNOLOGY 104 3.3.4.2 ALLOWABLE USE OF
FUNCTIONAL FEATURES 106 3.3.4.3 THE ONE WAY RULE - AN EXTREME
SOLUTION.... 107 3.3.4.4 FUNCTIONAL CLAIMS IN CASES OF DEPOSITION
....111 3.3.4.5 GENERALISATION FROM ONE TO MORE ORGANISMS 118 3.3.4.6
REMARKS 120 4. NOVELTY 130 4.1 THE NOVELTY PRINCIPLE 130 4.2 THE STATE
OF THE ART 132 4.2.1 ABSOLUTE AND GLOBAL NOVELTY - AN EXTENSIVE
DEFINITION OF THE STATE OF THE ART 132 4.2.2 THE SKILLED MAN MUST BE
ABLE TO USE THE STATE OF THE ART 134 4.3 NOVEL TECHNICAL FEATURES IN
PRODUCT PATENTS FOR ACTIVE SUBSTANCES 140 4.4 NOVELTY IN DIASTEREOMERS
AND ENANTIOMERS 146 4.5 A STARTING SUBSTANCE AND A PROCESS GIVING THE
CLAIMED SUBSTANCE 152 4.6 NOVELTY OF A METABOLITE IN RELATION TO ITS
KNOWN PRODRUG 154 4.7 SELECTION INVENTIONS 157 4.7.1 INTRODUCTION 157
4.7.2 SELECTION WITH FORMULAE AND WITH INDIVIDUAL SUBSTANCES 159 4.7.3
SELECTION FROM MARKUSH FORMULAE 161 4.7.4 SELECTION FROM AN UNLIMITED
NUMBER OF POSSIBILITIES .. 164 4.8 REMARKS 168 4.8.1 THE GLOBAL AND
ABSOLUTE NOVELTY REQUIREMENT 168 4.8.2 SELECTION INVENTIONS 170 5. NEW
MEDICAL USES OF KNOWN COMPOUNDS 177 5.1 NEW MEDICAL INDICATIONS AND THE
SYSTEMATISATION OF PATENT LAW 177 5.2 THE FIRST MEDICAL INDICATION 178
CONTENTS 15 5.2.1 THE BREADTH OF PATENT CLAIMS TO A FIRST MEDICAL
INDICATION 179 5.3 THE SECOND MEDICAL INDICATION 181 5.3.1 INTRODUCTION
OF PATENTS FOR A SECOND MEDICAL INDICATION 181 5.3.2 BREADTH OF CLAIMS
FOR A SECOND MEDICAL INDICATION ....186 5.4 NOVELTY ASSESSMENT OF
MEDICAL INDICATIONS 187 5.4.1 CHARACTERISTICS OF A NEW INDICATION 187
5.4.2 NEW BIOLOGICAL MECHANISM AS A NEW INDICATION 188 5.4.3 NEW
CATEGORY OF PATIENTS AS A NEW INDICATION 191 5.4.4 METHOD OF
ADMINISTRATION AS A NEW INDICATION 192 5.4.5 SELECTION INVENTIONS AND
NEW MEDICAL INDICATIONS 193 5.5 REMARKS 195 6. INVENTIVE STEP 198 6.1
INTRODUCTION 198 6.2 PROVISIONS ON INVENTIVE STEP 199 6.3 SPECIAL
CONDITIONS APPLYING TO PHARMACEUTICAL INVENTIONS 200 6.4 THE PROBLEM AND
SOLUTION METHOD 203 6.4.1 INTRODUCTION 203 6.4.2 THE THREE STEPS OF THE
METHOD 204 6.5 STEP 1 - THE CLOSEST PART OF THE STATE OF THE ART 205
6.5.1 CONSIDERATION OF TECHNICAL EFFECT AND STRUCTURE 205 6.5.2
UNREALISTIC PRIOR DOCUMENTS 207 6.5.3 CIRCUMSTANCES DISCLOSED AFTER THE
PRIORITY DATE 211 6.6 STEP 2 - ESTABLISHING THE PROBLEM 212 6.6.1 THE
PRINCIPLE OF PROBLEM FORMULATION 212 6.6.2 WHEN IS AN INVENTION AN
IMPROVEMENT? 213 6.6.-3 PROOF OF IMPROVED EFFECT 214 6.6.4 PARTIAL
IMPROVEMENTS 216 6.6.5 SUBMISSION OF NEW BENEFITS 218 6.7 STEP 3 - THE
SOLUTION 222 6.7.1 THE SOLUTION - THE FEATURES PRODUCING THE TECHNICAL
EFFECT 222 6.7.2 THE QUESTION TO BE ANSWERED 223 6.7.3 ALTERNATIVE
SUBSTANCES 226 6.7.4 STATEMENTS IN THE STATE OF THE ART 229 6.7.5
INVENTIVE STEP IN CONNECTION WITH AN IMPROVEMENT....234 6.8 OTHER
CONSIDERATIONS THAN STRUCTURE AND EFFECT 239 6.8.1 PRIOR DOCUMENTS OTHER
THAN THE CLOSEST 240 6.8.2 THE TIME FACTOR - FOR HOW LONG DID THE
PROBLEM EXIST? 246 6.8.3 COMMERCIAL INTEREST IN THE INVENTION 249 6.8.4
PROBLEM INVENTIONS AND INVENTIVE STEP 250 6.8.5 INVENTIVE STEP IN THE
CREATION OF BIOTECHNOLOGY 253 1 6 CONTENTS 6.9 REMARKS 259 6.9.1 AN
ECONOMIC INTERPRETATION OF INVENTIVE STEP 259 6.9.2 THE MARKET FOR THE
CREATION OF PHARMACEUTICAL INVENTIONS 262 7. SUPPLEMENTARY PATENT
PROTECTION 267 7.1 INTRODUCTION OF THE REGULATION AND ITS MAIN OUTLINES
267 7.2 PRODUCTS QUALIFYING FOR SUPPLEMENTARY PROTECTION 271 7.3 THE
EXTENT OF PROTECTION GRANTED 274 7.4 SEVERAL PATENTS REFERRING TO THE
SAME PRODUCT 280 7.5 REMARKS 281 8. PATENT INFRINGEMENT 287 8.1 ACTS OF
INFRINGEMENT 287 8.1.1 DIRECT PRODUCTS OF A PATENTED PROCESS 287 8.1.2
EXCEPTIONS FROM THE EXCLUSIVE RIGHT 290 8.1.3 EXHAUSTION OF THE PATENT
RIGHT - PARALLEL IMPORTS OF MEDICINAL PRODUCTS 290 8.1.4 THE EXPERIMENT
EXCEPTION 292 8.1.4.1 INTRODUCTION 292 8.1.4.2 FILING AN APPLICATION FOR
MARKETING AUTHORISATION 293 8.1.4.3 SUBMISSION OF SAMPLES OF MEDICINAL
PRODUCTS TO THE AUTHORISING AUTHORITY 294 8.1.4.4 EXPERIMENTS FOR THE
COLLECTION OF DATA 296 8.1.4.5 REMARKS 302 8.1.5 FORMULATION OF A
MEDICINE 309 8.2 THE SCOPE OF PATENT PROTECTION 311 8.2.1 GENERAL
PRINCIPLES 311 8.2.1.1 INTERPRETATIONS OF PATENT CLAIMS 311 8.2.1.2
EQUIVALENCE 314 8.2.2 PHARMACEUTICAL PATENTS 319 8.2.2.1 PRODUCT PATENTS
319 8.2.2.2 PRODUCT-BY-PROCESS CLAIMS 327 8.2.2.3 USE LIMITATIONS 329
8.2.2.4 PROCESSES 330 8.2.3 REMARKS 336 . 8.2.3.1 THE VALUE OF
CO-ORDINATION 336 8.2.3.2 THE HYPOTHESIS 339 8.2.3.3 CONCLUSIONS 342 9.
REFERENCES 345 9.1 TABLE OF CASES 345 9.2 BIBLIOGRAPHY 352 10. INDEX 361
|
| adam_txt |
BENGT DOMEIJ PHARMACEUTICAL PATENTS IN EUROPE INTERNATIONAL THE HAGUE *
LONDON * BOSTON NORSTEDTS JURIDIK STOCKHOLM CONTENTS ACKNOWLEDGEMENTS 7
FOREWORD 8 ABBREVIATIONS 17 1. INDUSTRIAL APPLICABILITY 19 1.1
INDUSTRIAL APPLICABILITY OF PHARMACEUTICAL PRODUCT PATENTS 19 1.2
REMARKS 25 1.3 INDUSTRIAL APPLICABILITY OF MEDICAL PROCESSES 30 1.3.1
PROCESSES APPLIED TO THE HUMAN OR ANIMAL BODY 30 1.3.2 THERAPY 31 1.3.3
DIAGNOSIS 35 1.3.4 REMARKS 38 2. SUFFICIENCY OF DISCLOSURE 45 2.1
DISCLOSURES OF INVENTIONS 45 2.2 THE MAN SKILLED IN THE ART 47 2.2.1 THE
DIFFERENT ASPECTS OF THE MAN SKILLED IN THE ART 47 2.2:2 THE SCOPE OF
KNOWLEDGE 48 2.2.3 THE AVERAGE KNOWLEDGE 52 2.2.4 THE EFFORT TO BE MADE
BY THE SKILLED PERSON 55 2.2.5 PARTS OF THE PATENT APPLICATION THAT THE
SKILLED MAN MAY USE 58 2.3 REMARKS 60 3. THE CLAIMS 63 3.1 TWO PURPOSES
63 3.2 CLARITY. '. 64 3.2.1 GENERAL RULES 64 3.2.2 CLARITY AND BROAD
CLAIMS 65 3.2.3 DEFINITIONS OF CHEMICAL COMPOUNDS 67 3.2.3.1 STRUCTURAL
FORMULA 68 3.2.3.2 PRODUCT-BY-PROCESS CLAIMS 68 3.2.3.3 PARAMETERS IN
THE CLAIMS 69 14 CONTENTS 3.3 THE RELATIONSHIP BETWEEN THE INVENTION AND
THE SCOPE OF PROTECTION 73 3.3.1 INTRODUCTION 73 3.3.2 THE OUTLINE OF
THE STUDY 74 3.3.3 STRUCTURAL FEATURES - MARKUSH CLAIMS 76 3.3.3.1
PROCEDURAL RULES 80 3.3.3.2 NON-FUNCTIONAL PARTS OF THE CLAIMS 82
3.3.3.3 REMARKS 85 3.3.4 FUNCTIONAL FEATURES 104 3.3.4.1 FUNCTIONAL
FEATURES - PARTICULARLY IN BIOTECHNOLOGY 104 3.3.4.2 ALLOWABLE USE OF
FUNCTIONAL FEATURES 106 3.3.4.3 THE ONE WAY RULE - AN EXTREME
SOLUTION. 107 3.3.4.4 FUNCTIONAL CLAIMS IN CASES OF DEPOSITION
.111 3.3.4.5 GENERALISATION FROM ONE TO MORE ORGANISMS 118 3.3.4.6
REMARKS 120 4. NOVELTY 130 4.1 THE NOVELTY PRINCIPLE 130 4.2 THE STATE
OF THE ART 132 4.2.1 ABSOLUTE AND GLOBAL NOVELTY - AN EXTENSIVE
DEFINITION OF THE STATE OF THE ART 132 4.2.2 THE SKILLED MAN MUST BE
ABLE TO USE THE STATE OF THE ART 134 4.3 NOVEL TECHNICAL FEATURES IN
PRODUCT PATENTS FOR ACTIVE SUBSTANCES 140 4.4 NOVELTY IN DIASTEREOMERS
AND ENANTIOMERS 146 4.5 A STARTING SUBSTANCE AND A PROCESS GIVING THE
CLAIMED SUBSTANCE 152 4.6 NOVELTY OF A METABOLITE IN RELATION TO ITS
KNOWN PRODRUG 154 4.7 SELECTION INVENTIONS 157 4.7.1 INTRODUCTION 157
4.7.2 SELECTION WITH FORMULAE AND WITH INDIVIDUAL SUBSTANCES 159 4.7.3
SELECTION FROM MARKUSH FORMULAE 161 4.7.4 SELECTION FROM AN UNLIMITED
NUMBER OF POSSIBILITIES . 164 4.8 REMARKS 168 4.8.1 THE GLOBAL AND
ABSOLUTE NOVELTY REQUIREMENT 168 4.8.2 SELECTION INVENTIONS 170 5. NEW
MEDICAL USES OF KNOWN COMPOUNDS 177 5.1 NEW MEDICAL INDICATIONS AND THE
SYSTEMATISATION OF PATENT LAW 177 5.2 THE FIRST MEDICAL INDICATION 178
CONTENTS 15 5.2.1 THE BREADTH OF PATENT CLAIMS TO A FIRST MEDICAL
INDICATION 179 5.3 THE SECOND MEDICAL INDICATION 181 5.3.1 INTRODUCTION
OF PATENTS FOR A SECOND MEDICAL INDICATION 181 5.3.2 BREADTH OF CLAIMS
FOR A SECOND MEDICAL INDICATION .186 5.4 NOVELTY ASSESSMENT OF
MEDICAL INDICATIONS 187 5.4.1 CHARACTERISTICS OF A NEW INDICATION 187
5.4.2 NEW BIOLOGICAL MECHANISM AS A NEW INDICATION 188 5.4.3 NEW
CATEGORY OF PATIENTS AS A NEW INDICATION 191 5.4.4 METHOD OF
ADMINISTRATION AS A NEW INDICATION 192 5.4.5 SELECTION INVENTIONS AND
NEW MEDICAL INDICATIONS 193 5.5 REMARKS 195 6. INVENTIVE STEP 198 6.1
INTRODUCTION 198 6.2 PROVISIONS ON INVENTIVE STEP 199 6.3 SPECIAL
CONDITIONS APPLYING TO PHARMACEUTICAL INVENTIONS 200 6.4 THE PROBLEM AND
SOLUTION METHOD 203 6.4.1 INTRODUCTION 203 6.4.2 THE THREE STEPS OF THE
METHOD 204 6.5 STEP 1 - THE CLOSEST PART OF THE STATE OF THE ART 205
6.5.1 CONSIDERATION OF TECHNICAL EFFECT AND STRUCTURE 205 6.5.2
UNREALISTIC PRIOR DOCUMENTS 207 6.5.3 CIRCUMSTANCES DISCLOSED AFTER THE
PRIORITY DATE 211 6.6 STEP 2 - ESTABLISHING THE PROBLEM 212 6.6.1 THE
PRINCIPLE OF PROBLEM FORMULATION 212 6.6.2 WHEN IS AN INVENTION AN
IMPROVEMENT? 213 6.6.-3' PROOF OF IMPROVED EFFECT 214 6.6.4 PARTIAL
IMPROVEMENTS 216 6.6.5 SUBMISSION OF NEW BENEFITS 218 6.7 STEP 3 - THE
SOLUTION 222 6.7.1 THE SOLUTION - THE FEATURES PRODUCING THE TECHNICAL
EFFECT 222 6.7.2 THE QUESTION TO BE ANSWERED 223 6.7.3 ALTERNATIVE
SUBSTANCES 226 6.7.4 STATEMENTS IN THE STATE OF THE ART 229 6.7.5
INVENTIVE STEP IN CONNECTION WITH AN IMPROVEMENT.234 6.8 OTHER
CONSIDERATIONS THAN STRUCTURE AND EFFECT 239 6.8.1 PRIOR DOCUMENTS OTHER
THAN THE CLOSEST 240 6.8.2 THE TIME FACTOR - FOR HOW LONG DID THE
PROBLEM EXIST? 246 6.8.3 COMMERCIAL INTEREST IN THE INVENTION 249 6.8.4
PROBLEM INVENTIONS AND INVENTIVE STEP 250 6.8.5 INVENTIVE STEP IN THE
CREATION OF BIOTECHNOLOGY 253 1 6 CONTENTS 6.9 REMARKS 259 6.9.1 AN
ECONOMIC INTERPRETATION OF INVENTIVE STEP 259 6.9.2 THE "MARKET" FOR THE
CREATION OF PHARMACEUTICAL INVENTIONS 262 7. SUPPLEMENTARY PATENT
PROTECTION 267 7.1 INTRODUCTION OF THE REGULATION AND ITS MAIN OUTLINES
267 7.2 PRODUCTS QUALIFYING FOR SUPPLEMENTARY PROTECTION 271 7.3 THE
EXTENT OF PROTECTION GRANTED 274 7.4 SEVERAL PATENTS REFERRING TO THE
SAME PRODUCT 280 7.5 REMARKS 281 8. PATENT INFRINGEMENT 287 8.1 ACTS OF
INFRINGEMENT 287 8.1.1 DIRECT PRODUCTS OF A PATENTED PROCESS 287 8.1.2
EXCEPTIONS FROM THE EXCLUSIVE RIGHT 290 8.1.3 EXHAUSTION OF THE PATENT
RIGHT - PARALLEL IMPORTS OF MEDICINAL PRODUCTS 290 8.1.4 THE EXPERIMENT
EXCEPTION 292 8.1.4.1 INTRODUCTION 292 8.1.4.2 FILING AN APPLICATION FOR
MARKETING AUTHORISATION 293 8.1.4.3 SUBMISSION OF SAMPLES OF MEDICINAL
PRODUCTS TO THE AUTHORISING AUTHORITY 294 8.1.4.4 EXPERIMENTS FOR THE
COLLECTION OF DATA 296 8.1.4.5 REMARKS 302 8.1.5 FORMULATION OF A
MEDICINE 309 8.2 THE SCOPE OF PATENT PROTECTION 311 8.2.1 GENERAL
PRINCIPLES 311 8.2.1.1 INTERPRETATIONS OF PATENT CLAIMS 311 8.2.1.2
EQUIVALENCE 314 8.2.2 PHARMACEUTICAL PATENTS 319 8.2.2.1 PRODUCT PATENTS
319 8.2.2.2 PRODUCT-BY-PROCESS CLAIMS 327 8.2.2.3 USE LIMITATIONS 329
8.2.2.4 PROCESSES 330 8.2.3 REMARKS 336 . 8.2.3.1 THE VALUE OF
CO-ORDINATION 336 8.2.3.2 THE HYPOTHESIS 339 8.2.3.3 CONCLUSIONS 342 9.
REFERENCES 345 9.1 TABLE OF CASES 345 9.2 BIBLIOGRAPHY 352 10. INDEX 361 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Domeij, Bengt |
| author_facet | Domeij, Bengt |
| author_role | aut |
| author_sort | Domeij, Bengt |
| author_variant | b d bd |
| building | Verbundindex |
| bvnumber | BV021451552 |
| ctrlnum | (OCoLC)247401924 (DE-599)BVBBV021451552 |
| dewey-full | 346.40486 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 346 - Private law |
| dewey-raw | 346.40486 |
| dewey-search | 346.40486 |
| dewey-sort | 3346.40486 |
| dewey-tens | 340 - Law |
| discipline | Rechtswissenschaft |
| discipline_str_mv | Rechtswissenschaft |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01099nam a2200313 c 4500</leader><controlfield tag="001">BV021451552</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20091216 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">000731s2000 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9041113487</subfield><subfield code="9">90-411-1348-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9139006018</subfield><subfield code="9">91-39-00601-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)247401924</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021451552</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">346.40486</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Domeij, Bengt</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical patents in Europe</subfield><subfield code="c">Bengt Domeij</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">The Hague [u.a.]</subfield><subfield code="b">Kluwer Law International [u.a.]</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">364 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Stockholm studies in law</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014671818&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014671818</subfield></datafield></record></collection> |
| id | DE-604.BV021451552 |
| illustrated | Not Illustrated |
| index_date | 2024-07-02T14:05:35Z |
| indexdate | 2024-07-09T20:36:17Z |
| institution | BVB |
| isbn | 9041113487 9139006018 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014671818 |
| oclc_num | 247401924 |
| open_access_boolean | |
| owner | DE-M382 DE-188 |
| owner_facet | DE-M382 DE-188 |
| physical | 364 S. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Kluwer Law International [u.a.] |
| record_format | marc |
| series2 | Stockholm studies in law |
| spelling | Domeij, Bengt Verfasser aut Pharmaceutical patents in Europe Bengt Domeij The Hague [u.a.] Kluwer Law International [u.a.] 2000 364 S. txt rdacontent n rdamedia nc rdacarrier Stockholm studies in law Includes index GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014671818&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Domeij, Bengt Pharmaceutical patents in Europe |
| title | Pharmaceutical patents in Europe |
| title_auth | Pharmaceutical patents in Europe |
| title_exact_search | Pharmaceutical patents in Europe |
| title_exact_search_txtP | Pharmaceutical patents in Europe |
| title_full | Pharmaceutical patents in Europe Bengt Domeij |
| title_fullStr | Pharmaceutical patents in Europe Bengt Domeij |
| title_full_unstemmed | Pharmaceutical patents in Europe Bengt Domeij |
| title_short | Pharmaceutical patents in Europe |
| title_sort | pharmaceutical patents in europe |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014671818&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT domeijbengt pharmaceuticalpatentsineurope |